Innovative patient access schemes for the adoption of new technology: Risk-sharing agreements;Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: Los acuerdos de riesgo compartido

Gaceta Sanitaria

Volumn 24, Issue 6, 2010, Pages 491-497

  Espín, Jaime ^a   Oliva, Juan ^b,c   Rodríguez Barrios, José Manuel ^d  

^a ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Health care policies and reimbursement; Patients access schemes; Risk sharing agreements; Sustainability; Uncertainty

Indexed keywords

ARTICLE; HEALTH CARE DELIVERY; HUMAN; MEDICAL TECHNOLOGY; RISK MANAGEMENT; SPAIN;

BIOMEDICAL TECHNOLOGY; HEALTH SERVICES ACCESSIBILITY; HUMANS; RISK SHARING, FINANCIAL; SPAIN;

EID: 78649630053     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2010.07.011     Document Type: Article

References (32)

1. Puig-Junoy J, Meneu R. Aplicación de los contratos de riesgo compartido a la financiación de nuevos medicamentos. Gestión Clínica y Sanitaria 2004, 7:88-93.
2. Towse A, Garrison LP. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 2010, 28:93-102.
3. The Pharmaceutical Price Regulation Scheme. December 2008. [consultado 11/4/2010]. Disponible en: http://www.dh.gov.uk/pprs.
4. Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment and health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96:179-90.
5. Espín J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. A study funded by DG Enterprise and Industry of the European Commission, EASP Final Report, June 2007. [consultado 1/4/2010]. Disponible en: http://ec.europa.eu/enterprise/phabiocom/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_incl_annexes.pdf.
6. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London; 2008.
7. Chapman S, Reeve E, Rajaratnam G, et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003, 326:707-709.
8. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010, 28:113-142.
9. IMS Pharma Pricing & Reimbursement. Velcade: the rise of risk-sharing in the UK. September 2007; Vol. 12, No. 9.
10. Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (the TAYLORx trial). [consultado 1/11/2010]. Disponible en: http://www.clinicaltrials.gov.
11. O'Malley SP, Selby WS, Jordan E. A successful practical application of coverage with evidence development in Australia: medical Services Advisory Committee interim funding and the PillCam capsule endoscopy register. Int J Technol Assess Health Care 2009, 25:290-296.
12. Rockman C. Reducing complications by better case selection: anatomic considerations. Semin Vasc Surg 2004, 17:298-306.
13. Endovascular stent-grafts for the treatment of abdominal aortic aneurysms. London (UK): National Institute for Health and Clinical Excellence (NICE); (Technology appraisal guidance; no. 167). London; 2009.
14. EVAR trial participants Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005, 365:2179-2186.
15. EVAR trial participants Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet 2005, 365:2187-2192.
16. Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S). Australian audit of endovascular aneurysm repair. Adelaide (SA): ASERNIP-S. 2006. [consultado 20/5/2009]. Disponible en: http://www.health.gov.au/internet/msac/publishing.nsf/Content/73490CB880736E01CA2575AD0082FD13/$File/Final%20AAA%20Progress%20Report%20Oct%2006.pdf.
17. Tarride JE, Blackhouse G, De RG, et al. Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: a 1-year patient-level analysis conducted in Ontario, Canada. J Vasc Surg 2008, 48:779-787.
18. Blackhouse G, Hopkins R, Bowen JM, et al. A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. Value Health 2008, 12:245-252.
19. Luengo S, Polo MM. Uso tutelado del tratamiento intraluminal de los aneurismas de aorta abdominal mediante prótesis intravasculares. Agencia de Evaluación de Tecnologías Sanitarias; 2005.
20. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ 2009, (early view).
21. Sudlow CLM, Counsell CE. Problems with the UK government's risk sharing scheme for assessing drugs for sclerosis. BMJ 2003, 326:388-392.
22. Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study - early results and lessons for the future. BMC Neurology 2009, 9:1.
23. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009; doi:. http://10.1136/bmj.b4677.
24. Ley 29/2006 de 26 de julio de garantías y uso racional de medicamentos y productos sanitarios. BOE núm. 178, de 27 de julio de 2006. pp. 28122-65.
25. RD 1030/2006 de 15 de septiembre por el que se establece la cartera de servicios comunes del Sistema Nacional de Salud y el procedimiento para su actualización.
26. Orden SCO/3422/2007, de 21 de noviembre, por la que se desarrolla el procedimiento de actualización de la cartera de servicios comunes del Sistema Nacional de Salud. BOE 285, de 25 de noviembre de 2007. pp. 48677-82.
27. Ministerio de Sanidad y Política Social. Informe del Sistema Nacional de Salud 2004-2007. Madrid; 2009.
28. Espinosa C, Gilabert A, Magem D, et al. Riesgo compartido: ¿por qué no? XXIX Jornadas de Economía de la Salud. Málaga; 2009.
29. Gilabert Perramón A, Magem Luque D, Espinosa Tomé C. Evaluaciones económicas y de impacto presupuestario en la gestión de la prestación farmacéutica en el CatSalut: ¿estamos preparados para el desafío? Boletín Economía y Salud. 2009; n.o 66.
30. Menon D, McCabe CJ, Stafinski T, et al. Principles of design of access with evidence development approaches. A consensus statement from the banff summit. Pharmacoeconomics 2010, 28:109-111.
31. Barros PP. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Economics. 2010; (early view).
32. Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010, 28:163-170.